Prior to the advent of anti–vascular endothelial growth factor (VEGF) therapy, vision loss from macular edema because of central retinal vein occlusion (CRVO) lacked a proven safe and effective treatment. Use of anti-VEGF therapy for vision loss arising from macular edema from CRVO has been reported as early as 2005.1 Since then, multiple randomized clinical trials have described the efficacy and safety of anti-VEGF therapy for the treatment of macular edema and vision loss from CRVO.2,3
Ip MS. Treatment of Central Retinal Vein Occlusion—A New Look at a Blast From the Past. JAMA Ophthalmol. 2018;136(12):1397–1398. doi:10.1001/jamaophthalmol.2018.4997
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: